Tumor suppression in vivo of DC vaccine modified by recombinant adenovirus Ad5F35-LMP2
10.3760/cma.j.issn.1003-9279.2010.04.011
- VernacularTitle:Ad5F35-LMP2重组腺病毒修饰DC体内特异性抗瘤作用的研究
- Author:
Wu-Ning MO
1
;
Zhan WANG
;
Ling ZHOU
;
Shao-Bing ZHAN
;
An-Zhou TANG
;
Guang-Wu HUANG
;
Yi ZENG
Author Information
1. 广西医科大学第一附属医院
- Keywords:
Adenovirus;
Herpesvirus 4,human;
Viralenvelope proteins;
Dendritic cells;
Tumor suppressor proteins
- From:
Chinese Journal of Experimental and Clinical Virology
2010;24(4):270-272
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe whether dendritic cells(DCs) transfected with recombinant adenovirus Ad5F35-LMP2 suppress the proliferation of CNE-2 in vivo. Methods Dendritic cells have been generated with the induction of IL-4,GM-CSF and TNF-a in vitro. After human PBMCs were transplant into SCID mice,SCID mice were vaccinated with Ad5F35-LMP2-DC or untransfected DC. And four days latter,CNE-2 (1×106cell for each mouse) inoculated into SCID mouse subcutaneously. The tumor growth was monitored every week. Results The tumor latent period of Ad5F35-LMP2-DC group is longer among three groups. Untransfected DC group and CNE-2 positive control group could be found tumor about one week, but Ad5F35-LMP2-DC group was about two weeks. And the tumor was smaller and lighter than untransfected DC group and CNE-2 positive control group. Average tumor control rate reached 64.75% compared with untransfected DC group. Conclusion Ad5F35-LMP2-DC could effectively suppress the proliferation of CNE2 in vivo.
